Clinical trial NCT03070405: The Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects
Official title: An Open-label, Randomized, Crossover Study to Evaluate the Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: Tenofovir Disoproxil Fumarate
4-Aminosalicylic Acid
Tuberculosis
HIV
Lead sponsor: Inje University
Sponsor class: OTHER
First posted: 2017-03-03
Enrollment: 20
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SCREENING

Brief summary: The main purpose of this study is to evaluate whether PAS will change the PK parameters of tenofovir.


Eligibility criteria: Inclusion Criteria:

1. Healthy adult male volunteers, ages 19 to 45 years at the time of screening test inclusive.
2. Subjects who did not have congenital or chronic diseases and sign and symptom after medical examinations
3. Body Mass Index (BMI) of 18 to 25 kg/m2, inclusive. BMI = weight (kg)/ \[height (m)\]2.
4. Volunteers deemed as appropriate subjects by investigators, after passing medical screening, including assessment of medical history, vital signs, 12-lead ECG, physical examination, laboratory tests etc. according to the characteristics of the investigational products.
5. Subjects who can participate in the whole clinical trial.
6. Subjects who voluntarily sign a written consent form after having received information regarding the objectives and contents of the trial, and characteristics of the study drug drugs prior to signing.

Exclusion Criteria:

1. Medical History

   1. Subjects with any disease or history of clinically significant liver, kidney, digestive system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, hemato-oncologic system, urinary system, cardiovascular system including arrhythmia.
   2. Subjects with any history of gastrointestinal diseases/conditions that could impact on the absorption of study drug.
2. Laboratory Test and ECG Findings

   1. Subjects who show, or have had clinical abnormalities detected through laboratory tests prior to the trial commencement date. Criteria for liver and renal function test are shown below:

      * AST or ALT above 1.25×ULN
      * Total bilirubin above 1.5×ULN
      * Serum creatinine clearance calculated by CKD-EPI below 80mL/min
   2. Subjects who show a clinically significant abnormalities detected through ECG
3. History of hypersensitivity to the drug including study drug ingredients and other medications (aspirin, antibiotics, etc.) or clinically significant hypersensitivity
4. Prohibition on Concomitant Drug/Food

   1. Use of ethical-the-counter/herbal preparations or use of over-the-counter medications/vitamin medications within 2 weeks or 1 week prior to study drug administration, respectively
   2. Subjects on any diet which could affected study drug's pharmacokinetics
   3. Subjects who administered the Probenecid, Penicillin G and other drugs which already known has an effect on OAT1 Transporter activity within 2 weeks prior to the first dose.
5. Blood Donation and Transfusion

   1. Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 60 days prior to study drug administration.
   2. Blood transfusion within 30 days prior to study drug administration.
6. Other Exclusion Criteria

   1. Alcohol over intake (alcohol \> 30g/day) and screening positive for alcohol
   2. Subjects who smoke within 3 months before initiation of clinical trial and subjects who cannot stop smoking during the participation of clinical study
   3. Subjects who cannot stop taking caffeine-containing foods (e.g. coffee, tea, green tea, cocoa, chocolate, soda, coffee milk, energy supplementary beverage, etc.) and alcoholic beverage during the participation of clinical study
   4. Subjects deemed to be inappropriate for the trial as determined by the investigator.

Primary outcomes:
measure: Peak plasma concentration (Cmax) of tenofovir
timeFrame: 0-84 hours in test and 0-72 hours in reference arm
measure: Area under the plasma concentration versus time curve (AUC) of tenofovir
timeFrame: 0-84 hours in test and 0-72 hours in reference arm
Secondary outcomes:
measure: Volume of distribution of tenofovir
timeFrame: 0-84 hours in test and 0-72 hours in reference arm
measure: Time of peak plasma concentration(Tmax) of tenofovir
timeFrame: 0-84 hours in test and 0-72 hours in reference arm
measure: Plasma half-life of tenofovir
timeFrame: 0-84 hours in test and 0-72 hours in reference arm
measure: Renal clearance of tenofovir
timeFrame: 0-24 hours
measure: Amount of tenofovir excreted in urine
timeFrame: 0-24 hours
measure: Peak plasma concentration of PAS
timeFrame: 0-12 hours
measure: Area under the plasma concentration versus time curve (AUC) of PAS
timeFrame: 0-12 hours
measure: Renal clearance of PAS
timeFrame: 0-12 hours
measure: Volume of distribution of PAS
timeFrame: 0-12 hours
measure: Time of peak plasma concentration of PAS
timeFrame: 0-12 hours
measure: Plasma half-life of PAS
timeFrame: 0-12 hours
measure: Amount of PAS excreted in urine
timeFrame: 0-12 hours
Other outcomes:
Locations:
Study officials:
affiliation: Inje University
name: Jae-Gook Shin, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: